| Previous Close | 15.72 |
| Open | 14.65 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 900 |
| Day's Range | 14.21 - 14.78 |
| 52 Week Range | 4.03 - 18.00 |
| Volume | 404,904 |
| Avg. Volume | 16,763 |
| Market Cap | 148.07M |
| Beta (5Y Monthly) | 1.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.92 |
| Earnings Date | May 05, 2021 - May 10, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.50 |
- ACCESSWIRE
Celcuity Prices Upsized Public Offering of Common Stock
MINNEAPOLIS, MN / ACCESSWIRE / February 24, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into 3rd generation diagnostics and expanded therapeutic options for cancer patients, today announced the pricing of its previously announced underwritten public offering of 1,714,000 shares of its common stock at a price to the public of $14.
- ACCESSWIRE
Celcuity Announces Proposed Public Offering of Common Stock
MINNEAPOLIS, MN / ACCESSWIRE / February 22, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into 3rd generation diagnostics and expanded therapeutic options for cancer patients, today announced that it has commenced an underwritten public offering of $20 million of shares of common stock.
- ACCESSWIRE
Celcuity Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
Announced a clinical trial collaboration in December with Massachusetts General Hospital, UCLA, and Vanderbilt and Puma Biotechnology to conduct a Phase II clinical trial.In January, announced a clinical trial collaboration with Sarah Cannon .
